quinoxalines has been researched along with 9,10-dimethyl-1,2-benzanthracene in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bergman, J; Möller, L; Rozell, BL; Skarin, T; Toftgård, R | 1 |
| Nagase, H; Saito, J; Sakai, Y | 1 |
2 other study(ies) available for quinoxalines and 9,10-dimethyl-1,2-benzanthracene
| Article | Year |
|---|---|
Protection against 12-O-tetradecanoylphorbol-13-acetate induced skin-hyperplasia and tumor promotion, in a two-stage carcinogenesis mouse model, by the 2,3-dimethyl-6(2-dimethylaminoethyl)-6H-indolo-[2,3-b]quinoxaline analogue of ellipticine.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Benzoyl Peroxide; Carcinogens; Dermatitis, Contact; Female; Hyperplasia; Indoles; Mice; Mice, Inbred SENCAR; Precancerous Conditions; Quinoxalines; Skin; Skin Neoplasms; Tetradecanoylphorbol Acetate | 1999 |
In vitro anti-mutagenic effect of magnolol against direct and indirect mutagens.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anthracenes; Antimutagenic Agents; Benzo(a)pyrene; Biphenyl Compounds; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Imidazoles; Kinetics; Lignans; Male; Methylnitronitrosoguanidine; Microsomes, Liver; Molecular Structure; Mutagenicity Tests; Mutagens; Oxidoreductases; Quinoxalines; Rats; Rats, Sprague-Dawley; Salmonella typhimurium | 2006 |